Anemia has become one of the most prevalent blood diseases. Anemia affects an estimated 3 million people in the United States, according to the National Heart, Lung, and Blood Institute. The rising incidence of target illnesses such as rheumatoid arthritis, autoimmune diseases, renal diseases, cancer, liver disorders, thyroid diseases, and inflammatory bowel diseases is a significant driver driving the market for intravenous iron medicines forward. Iron and vitamin deficiencies, as well as plastic, hemolytic, and sickle cell anemia, are among the most prevalent types of anemia. Iron, vitamin A, B12, and folate deficits are all frequent causes of anemia. Anemia is caused by infectious illnesses such as TB, parasitic infections, malaria, and HIV across the world. According to WHO statistics, anemia affects roughly 42 % of children under the age of five and 40 % of pregnant women.

Diabetes and hypertension are the two leading causes of CKD, according to the National Kidney Foundation, Inc. According to the same source, chronic renal disease affects around 10% of the worldwide population, with over 2 million people getting dialysis regularly. The bulk of these citizens are found in lands like Italy, the United States, Germany, Japan, and Brazil. The great majority of people who have the illness are unaware of it until severe symptoms appear. As the disease proliferates slowly in the body. Further, the incidence of chronic renal disease is expected to rise in developing economies like India and China, implying an increase in the elderly population in the future years. The need for intravenous iron medicines has increased dramatically as the frequency of these illnesses has increased.

In 2020, Europe had the second-largest revenue share in the market for intravenous iron medicines, and it is expected to rise rapidly over the forecast period. This is due to the presence of significant market participants on the ground, the increased research, and commercialization of new medications, the adoption of newer products, and the rising cancer incidence in the region. The introduction of new medicines has been a significant element in increasing iron drug use.

Despite a huge decline in the sales of products during the initial phase of pandemic spread and lockdown restrictions all over the region, the market is observed to pick up a quick pace for registering a CAGR of almost more than 8.5%, during the tenure of 2021 – 2027.

The report published by Maximize encompasses the market dynamics, which could affect the market growth of Intravenous Iron Drugs in the region, the Value – Chain Analysis, and the PORTER’s analysis for the Intravenous Iron Drugs market at a global level the study is associated based on major segments and further into sub-segments, by Product Type Iron Dextran, Iron Sucrose, Ferric Carboxymaltose, Others) and Applications (Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer, Others) to forecast the market size by value; also includes the analysis of past market dynamics from 2016 – 2020, considering 2020 as the base year.

Lastly, the market research report provides a regional comparison and a complete country- Vifor Pharma Management Ltd.; AMAG Pharmaceuticals; Daiichi Sankyo Company, Ltd. (American Regent. Inc.); Sanofi S.A.; Pharmacosmos A/S; Shield Therapeutics Plc; AbbVie Inc. (Allergan Plc), Sanofi, Luitpold Pharmaceuticals, Inc., Fresenius Medical Care AG & Co., Pharmacosmos A/S.

 You can browse the market data Tables and Figures spread through a comprehensive research report and in-depth TOC on the “Global Intravenous Iron Drugs Market.” 



Omkar Heights,

ManikBaug, Vadgaon Bk,

Sinhagad Road, Pune – 411051,

Maharashtra, India.

+91 9607195908


Leave a Replay

Your email address will not be published. Required fields are marked *